FDA Class II Recall: Heritage Pharmaceuticals' Desipramine Hydrochloride Tablets Hit by N-Nitroso Impurity
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. initiated a Class II recall for Desipramine Hydrochloride Tablets due to N-Nitroso Desipramine impurity exceeding acceptable limits. This event, linked to manufacturing by USV Private Limited in India, signals critical CGMP deviations. Procurement and regulatory teams must assess supply chain vulnerabilities for Desipramine Hydrochloride and enhance impurity testing protocols to mitigate commercial and patient safety risks.
FDA Findings: Heritage Pharmaceuticals' Desipramine Hydrochloride Recalled Over N-Nitroso Impurity
The U.S. Food and Drug Administration (FDA) has announced a Class II recall (D-0112-2026) initiated by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. for specific lots of Desipramine Hydrochloride Tablets, USP, 150 mg. The recall, voluntarily initiated by the firm on October 6, 2025, stems from critical Current Good Manufacturing Practice (CGMP) deviations, specifically the presence of N-Nitroso Desipramine impurity. This impurity was found to exceed the permissible acceptable daily intake (ADI) level, posing a significant quality and safety concern. The affected product, identified by NDC 23155-583-25 for the 50-count bottle, was distributed U.S. Nationwide, with 3,750 bottles from Lot#: 18035739 (Exp. Date: 11/30/2025) subject to this action. For procurement directors, this means an immediate re-evaluation of current inventory and future sourcing strategies for Desipramine Hydrochloride. The Class II classification indicates that the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This necessitates prompt action to mitigate potential supply chain disruptions and ensure patient safety.
International Supply Chain Vulnerability: Desipramine Hydrochloride Sourcing Implications
This recall highlights a critical vulnerability within the global pharmaceutical supply chain for Desipramine Hydrochloride. While Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. is the recalling firm based in East Brunswick, NJ, United States, the specific recalled lot (Lot#: 18035739) of Desipramine Hydrochloride Tablets, USP, 150 mg, was manufactured by USV Private Limited in Daman, India. This international manufacturing arrangement means that regulatory affairs and supply chain VPs must extend their scrutiny beyond the immediate distributor to the upstream API and finished product manufacturers. The presence of CGMP deviations at the manufacturing site, leading to an N-Nitroso impurity, underscores the imperative for rigorous supplier qualification and ongoing oversight, particularly for overseas partners. Businesses relying on this specific product (ANDA207433) must assess their exposure to similar quality risks across their entire supplier network, implementing enhanced audit programs and quality agreements to ensure compliance with FDA standards, regardless of the manufacturing geography.
N-Nitroso Impurities: A Persistent Industry-Wide Quality Challenge for Pharmaceuticals
The detection of N-Nitroso Desipramine exceeding acceptable daily intake levels is not an isolated incident but rather indicative of a broader, persistent challenge facing the pharmaceutical industry regarding nitrosamine impurities. These compounds are classified as probable human carcinogens, and their presence in drug products has led to numerous recalls across various therapeutic areas globally. For regulatory affairs heads and quality assurance teams, this event with Desipramine Hydrochloride Tablets reinforces the critical need for comprehensive nitrosamine risk assessments across all product portfolios. This includes evaluating potential sources of nitrosamines – from raw materials and APIs to manufacturing processes and packaging components. Implementing advanced analytical testing methods, such as GC-MS or LC-MS/MS, capable of detecting these impurities at very low levels, is paramount. Proactive identification and mitigation strategies are essential to prevent future recalls, protect patient safety, and maintain market access for essential medicines, ensuring business continuity in a stringent regulatory environment.
Strategic Sourcing and Alternative Supply for Desipramine Hydrochloride
Given the ongoing Class II recall of Desipramine Hydrochloride Tablets, USP, 150 mg, procurement directors must immediately activate contingency plans to secure alternative sources for this critical antidepressant. While the ChemLifeIntel Knowledge Graph does not identify specific alternative suppliers, the strategic imperative is to diversify the supply base to mitigate future single-source dependencies. This involves identifying and rigorously qualifying new manufacturers for Desipramine Hydrochloride, both API and finished product, with a strong emphasis on their track record of CGMP compliance and robust impurity control programs, particularly for nitrosamines. Qualification timelines can be extensive, often requiring several months for audits, analytical method transfers, and stability testing. Therefore, initiating this process without delay is crucial. Businesses should prioritize suppliers with established FDA approvals and a history of transparent quality data, potentially exploring manufacturers in different geographical regions to enhance supply chain resilience and reduce exposure to localized regulatory issues or manufacturing disruptions.
Regulatory Compliance and Remediation Path for Heritage Pharmaceuticals
The 'Ongoing' status of this Class II recall signifies that Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., along with its manufacturing partner USV Private Limited, is actively engaged in addressing the CGMP deviations and N-Nitroso Desipramine impurity issue. For regulatory affairs heads, this situation underscores the intense scrutiny companies face post-recall. Heritage/Avet will be required to conduct a thorough investigation into the root cause of the impurity, implement comprehensive corrective and preventive actions (CAPAs), and provide detailed updates to the FDA. Failure to adequately address these issues could lead to further regulatory enforcement, including potential Warning Letters, import alerts for the manufacturing facility in India, or even product withdrawal. The broader industry must recognize that such events can trigger increased FDA oversight on similar products or manufacturing processes, prompting a need for all stakeholders to proactively review their compliance frameworks and ensure their quality management systems are robust enough to prevent and detect such critical deviations.
Commercial and Market Impact of the Desipramine Hydrochloride Recall
The recall of 3,750 bottles of Desipramine Hydrochloride Tablets, USP, 150 mg, distributed U.S. Nationwide, presents immediate commercial implications for Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. and its downstream partners. Beyond the direct costs of the recall itself—including logistics, destruction, and customer communication—there is a significant risk of reputational damage and potential loss of market share for their Desipramine Hydrochloride product line. For business development executives and supply chain VPs, this event signals potential short-term market shortages for this specific dosage and formulation, necessitating adjustments in forecasting and inventory management. Healthcare providers and pharmacies relying on this product (ANDA207433) will need to identify alternative sources or formulations, potentially impacting patient access to this important medication. Proactive communication with customers and transparent remediation efforts will be critical for Heritage/Avet to mitigate long-term commercial fallout and rebuild trust within the pharmaceutical supply chain.